91奇迹

 找回密码
 中文注册
查看: 1534|回复: 1

化疗和靶向耐药的一个新希望?

[复制链接]
发表于 2008-10-28 21:41:39 | 显示全部楼层 |阅读模式 来自: 中国福建福州
抗糖尿病药物罗格列酮+卡铂, 应对化疗和靶向耐药?


Original Published:Clin Cancer Res.2008 Oct 15;14(20):6478-86.

Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK.

Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

PURPOSE: Current therapy for lung cancer involves multimodality therapies. However, many patients are either refractory to therapy or develop drug resistance. KRAS and epidermal growth factor receptor (EGFR) mutations represent some of the most common mutations in lung cancer, and many studies have shown the importance of these mutations in both carcinogenesis and chemoresistance. Genetically engineered murine models of mutant EGFR and KRAS have been developed that more accurately recapitulate human lung cancer. Recently, using cell-based experiments, we showed that platinum-based drugs and the antidiabetic drug rosiglitazone (PPARgamma ligand) interact synergistically to reduce cancer cell and tumor growth. Here, we directly determined the efficacy of the PPARgamma/carboplatin combination in these more relevant models of drug resistant non-small cell lung cancer. EXPERIMENTAL DESIGN: Tumorigenesis was induced by activation of either mutant KRAS or EGFR. Mice then received either rosiglitazone or carboplatin monotherapy, or a combination of both drugs. Change in tumor burden, pathology, and evidence of apoptosis and cell growth were assessed. RESULTS: Tumor burden remained unchanged or increased in the mice after monotherapy with either rosiglitazone or carboplatin. In striking contrast, we observed significant tumor shrinkage in mice treated with these drugs in combination. Immunohistochemical analyses showed that this synergy was mediated via both increased apoptosis and decreased proliferation. Importantly, this synergy between carboplatin and rosiglitazone did not increase systemic toxicity. CONCLUSIONS: These data show that the PPARgamma ligand/carboplatin combination is a new therapy worthy of clinical investigation in lung cancers, including those cancers that show primary resistance to platinum therapy or acquired resistance to targeted therapy.

[ 本帖最后由 yidiyidi 于 2008-10-28 22:21 编辑 ]
有爱,就有奇迹!
发表于 2008-10-29 01:54:53 | 显示全部楼层 来自: 美国
可惜只是白鼠实验
有爱,就有奇迹!
您需要登录后才可以回帖 登录 | 中文注册

本版积分规则

QQ|关于我们|隐私服务条款|小黑屋|手机版|91奇迹 ( 京ICP备2020048145号-6 )

GMT+8, 2024-11-23 15:41 , Processed in 0.039386 second(s), 18 queries .

Powered by Discuz! X3.4

Copyright © 2001-2023, Tencent Cloud.

快速回复 返回顶部 返回列表